Bio View

Bio View Equity

The The Equity of Bio View (BIOV.TA) as of Oct 19, 2026 is 9.42 M ILS. In the previous year, The Equity was 22.95 M ILS — a change of -58.97% (lower).

Equity

9.42 MILS

YoY

-58.97%

Last updated:

In 2025, Bio View's equity was 9.42 M ILS, a -58.97% increase from the 22.95 M ILS equity in the previous year.

The Bio View Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
22.75 M ILS
Jan 1, 2019
24.95 M ILS
Jan 1, 2020
25.07 M ILS
Jan 1, 2021
27.16 M ILS
Jan 1, 2022
28.28 M ILS
Jan 1, 2023
27.31 M ILS
Jan 1, 2024
22.95 M ILS
Jan 1, 2025
9.42 M ILS
The Bio View Equity history
YEAREquityYoY
9.42 MILS-58.97%
22.95 MILS-15.96%
27.31 MILS-3.43%
28.28 MILS+4.11%
27.16 MILS+8.34%
25.07 MILS+0.48%
24.95 MILS+9.68%
22.75 MILS-3.01%
23.46 MILS-15.03%
27.61 MILS+20.08%
22.99 MILS+26.43%
18.18 MILS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Bio View Stock analysis

What does Bio View do? Bio View Ltd, based in Rehovot, Israel, operates in the Health Care sector, specializing in the research, development, marketing, and sales of advanced imaging systems. The company manufactures and services the Duet workstation, an automated cell diagnostic system used in cytology, hematology, and pathology laboratories for detecting and analyzing abnormal cells. It also offers the ALLEGRO and ACCORD workstations for specialized applications in cancer diagnosis, minimal-residual disease monitoring, and FISH-based analyses in cytogenetics and oncology. Bio View is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bio View's Equity

Bio View's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bio View's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bio View's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bio View's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bio View’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bio View stock

The Equity of Bio View is 9.42 M ILS in 2025.

The Equity of Bio View changed from 22.95 M ILS to 9.42 M ILS, representing a -58.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Bio View since 2006 – with annual values, charts, and detailed analysis.

The Equity's ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bio View historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Bio View

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Bio View